Reimbursed Care Access in Honduras

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Honduras' drug-control framework and recent penal jurisprudence treat psychotropic substances consistent with the international conventions referenced in the Code and related drug statutes; therefore psilocybin is not available as a reimbursed medical therapy and access would be limited to sanctioned clinical trials only. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, trafficking, and distribution of MDMA are prosecuted under Honduras' drug laws and Penal Code provisions that apply the international psychotropic substances schedules; there is no publicly available framework for reimbursement or routine medical prescribing of MDMA-assisted therapy. #.

Esketamine (intranasal Spravato®) is an internationally developed, regulated antidepressant product with restricted distribution programs in markets where manufacturers have sought authorization; Janssen/SPRAVATO information indicates approved supply and REMS-like restricted programs in multiple jurisdictions, but there is no public record of a Honduran regulatory marketing authorization or a national reimbursement policy for esketamine as of February 20, 2026. Where esketamine is available in other countries it is provided under strict medical programs (specialized clinics, supervised administration, and risk‑mitigation measures) and typically through private specialty care channels rather than broad public formularies. For context, Spravato's manufacturer documentation describes restricted distribution and approved indications in markets where it is authorized. #.

Practical implication for Honduras: absent a national regulatory approval and a public reimbursement pathway, esketamine would only be accessible via (1) formal clinical trials approved by Honduran health authorities and ethics committees, or (2) importation under exceptional patient‑specific import authorization (compassionate use) if the Secretaría de Salud or equivalent regulator grants such an authorization—both pathways are exceptional, not routine, and would not imply government reimbursement. Honduras' drug-control and penal framework also treats psychotropic substances in alignment with international conventions, so routine, reimbursed access is not in place domestically. #.

Ketamine is an established anesthetic and analgesic included on the World Health Organization Model List of Essential Medicines and is therefore routinely registered and used within hospital and surgical settings worldwide; this global status supports its legal medical availability in most national health systems, including Honduras, for anesthesia and acute pain management. #.

Regulatory & reimbursement context in Honduras: Honduran law and judicial interpretation of drug offenses reference international scheduling conventions and impose criminal penalties for unauthorized trafficking or distribution of psychotropic substances; however, the presence of the WHO Essential Medicines listing and established clinical anesthetic practice means ketamine is legally used in hospitals and clinics for anesthesia and pain—medical uses that are part of routine (public and private) healthcare delivery rather than a permissive pathway for psychedelic-assisted psychotherapy. Public reimbursement specifics (coverage under Honduras' Secretaría de Salud primary-care or hospital formularies) are not published centrally in a manner that creates a standardized, nationwide reimbursed psychiatric ketamine therapy program; instead, ketamine is principally available as a medical/surgical anesthetic covered in the regular funding/operation of hospitals and private clinics, while its use for psychiatric indications (sub‑anesthetic infusions for depression, PTSD, etc.) is typically off‑label, provided privately, and not part of an established national reimbursement benefit. #; #.

Clinical/practical nuances: (1) Anesthesia and acute pain uses: routinely available in hospitals and generally incorporated into clinical care budgets. (2) Psychiatric/off‑label use: increasingly offered worldwide in private clinics but in Honduras would be delivered outside a standardized reimbursed program—patients typically pay privately or access such care via research protocols. (3) Safety/regulation: repeated or chronic off‑label psychiatric ketamine requires clinical governance (liver monitoring, cardiovascular monitoring, supervised administration) but such protocols are not nationally codified for psychiatric indications in Honduras in publicly available policy documents. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and DMT‑containing preparations are treated under Honduras' psychotropic substances framework and are not part of routine medical or reimbursed care. Access would be limited to sanctioned clinical research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is not recognized within Honduran medical formularies and would only be accessible, if at all, via formal approved research protocols. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine has no established, reimbursed medical pathway in Honduras and its importation or clinical use would require exceptional regulatory approvals; otherwise, possession/trafficking is prosecuted under the national drug laws. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While ayahuasca is a plant‑based preparation containing DMT and has traditional/ritual use in some Latin American contexts, Honduras does not provide a national legal/reimbursement pathway for ayahuasca ceremonies as medical treatment; any use outside traditional religious contexts would fall under psychotropic‑substance controls. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and peyote containing mescaline) is not part of any Honduran reimbursed medical program and is controlled under the nation's drug statutes aligned with international psychotropic controls. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel psychoactive phenethylamines in the 2C family are controlled and criminalized under Honduras' drug laws; there is no medical/reimbursed access. #.